Twist Bioscience Corporation filings document formal disclosures for a synthetic biology company with a silicon-based DNA synthesis platform. Form 8-K reports furnish quarterly and annual financial results, preliminary revenue information and business highlights tied to products and services such as synthetic DNA, NGS workflow tools and antibody discovery solutions.
The filing record also covers unregistered common stock issuances connected to licensing and technology-transfer arrangements, annual meeting voting results, director elections, auditor ratification, executive compensation votes, board appointments, committee service and director compensation. These disclosures address governance, capital structure and material events for TWST common stock.
Twist Bioscience Corp director Jan Johannessen reported an option exercise and related share sale. Johannessen exercised employee stock options for 12,000 shares of common stock at $14.00 per share, increasing his holdings to 29,754 shares. On the same day, he completed an open-market sale of 12,000 common shares at an average price of $56.12 per share, leaving him with 17,754 shares held directly after the transactions. The options exercised had vested in stages over several years, subject to his continuous service.
Twist Bioscience Corp Chief Accounting Officer Robert F. Werner reported an open-market sale of Common Stock. He sold 4,961 shares on May 8, 2026 at a price of $56.881 per share. After this transaction, he directly holds 49,674 shares of Twist Bioscience Common Stock.
TWST affiliate reported resale notices under Form 144 for small, recent dispositions. The filing lists three resale transactions by Robert F. Werner: 1,693 shares for $79,079.70 on 02/23/2026, 246 shares for $11,420.85 on 03/06/2026, and 164 shares for $9,372.40 on 05/04/2026. The filing also lists multiple scheduled Restricted Stock Vesting items with dates and share counts (examples include 1,062 shares vesting 08/22/2024 and 977 shares vesting 02/22/2026).
Twist Bioscience Corp ownership update: William Blair Investment Management, LLC filed Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 5,269,718 shares of Common Stock, representing 8.6% of the class. The filer reports sole voting power over 4,836,983 shares and sole dispositive power over 5,269,718 shares. The filing is signed by the Chief Compliance Officer on 05/07/2026.
Twist Bioscience Corp officer Dennis Cho reported a small mandated share sale linked to tax withholding. On May 4, 2026, he sold 1,962 shares of common stock at $57.1488 per share to cover taxes due on vesting Restricted Stock Units. After this transaction, he directly holds 135,941 shares of Twist Bioscience common stock, and the filing notes these sales were required under the company’s equity incentive plan and were not discretionary trades.
Twist Bioscience Corp Chief Executive Officer Emily M. Leproust reported an open-market sale of 5,127 shares of Common Stock at an average price of $57.1488 per share. According to the disclosure, these shares were sold to cover tax withholding obligations related to vesting Restricted Stock Units under the company’s equity incentive plans and are described as non-discretionary "sell to cover" transactions.
Following this tax-related sale, Leproust directly holds 853,760 shares of Common Stock. She also holds an employee stock option that is exercisable for 64,950 shares of Common Stock at an exercise price of $67.8500 per share, with an expiration date of August 31, 2030.
Twist Bioscience Corp President and COO Patrick John Finn reported an open-market sale of 2,844 shares of common stock at an average price of $57.1488 per share. The footnote explains these shares were sold solely to cover tax withholding obligations arising from the vesting of Restricted Stock Units under the company’s equity incentive plans.
The filing states these “sell to cover” transactions are mandated by the issuer’s plan election and are not discretionary trades by the executive. After this tax-related sale, Finn directly holds 278,964 shares of Twist Bioscience common stock.
Twist Bioscience Corp SVP Paula Green reported an open-market sale of 1,116 shares of common stock at $57.1488 per share. According to the disclosure, this sale was required to cover tax withholding obligations tied to the vesting of Restricted Stock Units under the company’s equity incentive plans and was not a discretionary trade. After the transaction, she directly holds 122,988 shares of Twist Bioscience common stock.
Twist Bioscience Corp’s Chief Accounting Officer Robert F. Werner reported a small, mandated share sale tied to equity compensation taxes. On May 4, 2026, he sold 164 shares of common stock at $57.1488 per share to cover tax withholding from vesting Restricted Stock Units.
The company’s equity incentive plan requires these “sell-to-cover” transactions, and the footnote states they are not discretionary trades by Werner. After this tax-related sale, he directly owns 54,635 shares of Twist Bioscience common stock.